Passion for Regeneration

Company Introduction

  • The new trend of regenerative medicine. PharmaResearch Co., Ltd. is a biopharmaceutical firm which realizes a new treatment paradigm for regenerative medicine which may be applied in various corners of life central to PDRN and PN, which are new concept tissue regenerating active substances.
  • Investing in the development of the biopharmaceutical industry. We utilize domestic natural resources and unique core technology to offer pharmaceutical products, medical devices and cosmetic products, etc., and contribute to the growth of the high value added biomedical industry.
  • To improve human quality of life, and the desire of the human health and longevity. Moving forward, we will continue to improve quality of life for people and contribute to extending life by introducing excellent products across the areas of regenerative medicine and anti-aging based on our continuing research and development endeavors, while realizing our strongest desire for healthy and beautiful later years in life.

CEO Message

The goal of the human race to improve the healthy and beautiful quality of life.

We sincerely thank all of you who trust and encourage PharmaResearch.

Since its founding in 1993, our company has expanded its business area starting from consulting for drug licensing, import and sales of innovative drugs. In 2009, we completed the manufacturing technology of PDRN, a tissue regenerative raw material using marine resources, for the first time in Korea. We laid the foundation as a comprehensive pharmaceutical company by obtaining certification as a pharmaceutical GMP factory in 2013, listing on the KOSDAQ in July 2015, and being certified as an Innovative Pharmaceutical Company in 2016.

Furthermore, PharmaResearch has a pipeline for "Total Aesthetic Solution" with reinforced PDRN-based pharmaceuticals, aesthetic medical devices, and derma-cosmetics, and adding lineup of botulinum toxin product through business expansion. We are preparing for a second leap forward in the anti-aging market.

In addition, we will not stop trying until the day that we are recognized as a global pharmaceutical company leading the improvement of quality of life and regenerative medicine as strengthening our network with domestic and overseas excellent research institutions and global bio-companies.

We kindly ask for your support for development and growth of PharmaResearch.
Thank you.

Chairman Jung Sangsoo


  1. 2020
    • Selected as KOSDAQ Right Star by the Korea Exchange
    • Awarded the ‘Excellent Companies to Work’ at Gangwon-do
    • Class 2 medical device approval and launch of REJUMATE® Injector
    • Expansion and relocation of Pangyo Office (62, Pangyo-ro 255beon-gil)
  2. 2019
    • CONJURAN® listed as New Health Technology (NECA)
    • 2nd Gangneung GMP factory completed
    • Extension of certification as an Innovative Pharmaceutical Company (MOHW)
  3. 2018
    • Acquisition of CLEVIEL business unit from Aestura
    • Est. PharmaResearch BIO, a bio-venture company specializing in biological products
  4. 2017
    • REJURAN CE certified
    • REJURAN Healer Cosmetics launched
    • Awarded the Industrial Award for Conservation of Fisheries Resources
    • Awarded 10 Million-dollar Export Tower
    • Started construction of 2nd Gangneung GMP factory
    • Signed a binding MOU for acquisition of BIOCND
  5. 2016
    • Joint research agreement of functional peptide
    • Certified as an Innovative Pharmaceutical Company
    • Acquisition of DRJ Organic Cosmetics
    • D+CELL Cosmetics lineup expansion
    • REJURAN i, REJURAN s launched
    • Acquired patent for thermosensitive hydrogel
  6. 2015
    • Released Rejuvenex injection, Re-An eye drops
    • Listed on KOSDAQ
  7. 2014
    • Registered PDRN DMF
    • Released Rejuran
    • Opend Anti-Aging Regenerative Medicine Research Center(Pangyo)
  8. 2013
    • Completed construction of GMP plant in Gangneung and approval obtained for manufacturing business
  1. 2008
    • Approval obtained for Placentex injection, a tissue regenerative medicine
    • Study of PDRN's Localization(cooperation width KIST)
  2. 2007
    • Executed cxclusive sales contract with Mastelli of Italy
    • Released ATP injection, a metabolism activation drug
  3. 2004
    • Released JBP
  4. 2002
    • Introduced BTXA (Botox of China) to Korean market
  5. 2000
    • Relesed Zadaxin, an anti-cancer immune modulating drug
  1. 1994
    • Executed contract with Omron of Japan
    • Launched product license and authorization developement consulting service (approximately 700 products licensed and authorized)
  2. 1993
    • Korea's first pharmaceutical consulting firm

Mission & Vision



With constant passion and a spirit of challenge, we aim to contribute to humanity and society by realizing the dream of improving the quality of life and extending healthy life with the development of regenerative medicine.

  • Challenges for Innovation

  • Cooperation on Achievements

  • Communication with Respect

  • Autonomy and Responsibility